These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 25104632)

  • 21. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
    Fernandes S; Sicuri E; Kayentao K; van Eijk AM; Hill J; Webster J; Were V; Akazili J; Madanitsa M; ter Kuile FO; Hanson K
    Lancet Glob Health; 2015 Mar; 3(3):e143-53. PubMed ID: 25701992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
    Ochalek J; Lomas J
    Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study.
    Bórquez A; Guanira JV; Revill P; Caballero P; Silva-Santisteban A; Kelly S; Salazar X; Bracamonte P; Minaya P; Hallett TB; Cáceres CF
    Lancet Public Health; 2019 Mar; 4(3):e127-e136. PubMed ID: 30683587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models.
    Bershteyn A; Jamieson L; Kim HY; Platais I; Milali MP; Mudimu E; Ten Brink D; Martin-Hughes R; Kelly SL; Phillips AN; Bansi-Matharu L; Cambiano V; Revill P; Meyer-Rath G; Nichols BE
    Lancet Glob Health; 2022 Sep; 10(9):e1298-e1306. PubMed ID: 35961353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults.
    Sun D; Dorman S; Shah M; Manabe YC; Moodley VM; Nicol MP; Dowdy DW
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):552-8. PubMed ID: 23485389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.
    Marseille E; Giganti MJ; Mwango A; Chisembele-Taylor A; Mulenga L; Over M; Kahn JG; Stringer JS
    PLoS One; 2012; 7(12):e51993. PubMed ID: 23284843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.
    Ryan M; Griffin S; Chitah B; Walker AS; Mulenga V; Kalolo D; Hawkins N; Merry C; Barry MG; Chintu C; Sculpher MJ; Gibb DM
    AIDS; 2008 Mar; 22(6):749-57. PubMed ID: 18356605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
    Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
    PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
    Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
    AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of interventions for HIV/AIDS, malaria, syphilis, and tuberculosis in 128 countries: a meta-regression analysis.
    Silke F; Earl L; Hsu J; Janko MM; Joffe J; Memetova A; Michael D; Zheng P; Aravkin A; Murray CJL; Weaver MR
    Lancet Glob Health; 2024 Jul; 12(7):e1159-e1173. PubMed ID: 38876762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV.
    Gopalappa C; Stover J; Shaffer N; Mahy M
    AIDS; 2014 Jan; 28 Suppl 1():S5-14. PubMed ID: 24468947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.
    Menzies NA; Gomez GB; Bozzani F; Chatterjee S; Foster N; Baena IG; Laurence YV; Qiang S; Siroka A; Sweeney S; Verguet S; Arinaminpathy N; Azman AS; Bendavid E; Chang ST; Cohen T; Denholm JT; Dowdy DW; Eckhoff PA; Goldhaber-Fiebert JD; Handel A; Huynh GH; Lalli M; Lin HH; Mandal S; McBryde ES; Pandey S; Salomon JA; Suen SC; Sumner T; Trauer JM; Wagner BG; Whalen CC; Wu CY; Boccia D; Chadha VK; Charalambous S; Chin DP; Churchyard G; Daniels C; Dewan P; Ditiu L; Eaton JW; Grant AD; Hippner P; Hosseini M; Mametja D; Pretorius C; Pillay Y; Rade K; Sahu S; Wang L; Houben RMGJ; Kimerling ME; White RG; Vassall A
    Lancet Glob Health; 2016 Nov; 4(11):e816-e826. PubMed ID: 27720689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis.
    Ryckman T; Weiser J; Gombe M; Turner K; Soni P; Tarlton D; Mazhidova N; Churchyard G; Chaisson RE; Dowdy DW
    Lancet Glob Health; 2023 Aug; 11(8):e1205-e1216. PubMed ID: 37474228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
    Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
    Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.